Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning?

Literature DB >> 22331930

Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning?

Hope S Rugo.

Abstract

Entities: Disease

Mesh：

Year: 2012 PMID： 22331930 DOI： 10.1200/JCO.2011.38.5492

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

18 in total

Review 1. Emerging targeted agents in metastatic breast cancer.

Authors: Dimitrios Zardavas; José Baselga; Martine Piccart
Journal: Nat Rev Clin Oncol Date: 2013-03-05 Impact factor: 66.675

2. VEGF₁₆₅b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop.

Authors: Asma Boudria; Cherine Abou Faycal; Tao Jia; Stephanie Gout; Michelle Keramidas; Chloé Didier; Nicolas Lemaître; Sandra Manet; Jean-Luc Coll; Anne-Claire Toffart; Denis Moro-Sibilot; Corinne Albiges-Rizo; Véronique Josserand; Eva Faurobert; Christian Brambilla; Elisabeth Brambilla; Sylvie Gazzeri; Beatrice Eymin
Journal: Oncogene Date: 2018-09-07 Impact factor: 9.867

Review 3. Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.

Authors: Robert S Kerbel
Journal: J Mammary Gland Biol Neoplasia Date: 2012-09-26 Impact factor: 2.673

4. A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.

Authors: Luigi Coltelli; Giacomo Allegrini; Paola Orlandi; Chiara Finale; Andrea Fontana; Luna Chiara Masini; Marco Scalese; Giada Arrighi; Maria Teresa Barletta; Ermelinda De Maio; Marta Banchi; Elisabetta Fini; Patrizia Guidi; Giada Frenzilli; Sara Donati; Simona Giovannelli; Lucia Tanganelli; Barbara Salvadori; Lorenzo Livi; Icro Meattini; Ilaria Pazzagli; Marco Di Lieto; Mirco Pistelli; Virginia Casadei; Antonella Ferro; Samanta Cupini; Francesca Orlandi; Damiana Francesca; Giulia Lorenzini; Leonardo Barellini; Alfredo Falcone; Alessandro Cosimi; Guido Bocci
Journal: NPJ Breast Cancer Date: 2022-03-21

5. Combining functional genomics strategies identifies modular heterogeneity of breast cancer intrinsic subtypes.

Authors: Nima Pouladi; Richard Cowper-Sallari; Jason H Moore
Journal: BioData Min Date: 2014-12-29 Impact factor: 2.522

6. A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer.

Authors: Long Bai; Feng Wang; Dong-Sheng Zhang; Cong Li; Ying Jin; De-Shen Wang; Dong-Liang Chen; Miao-Zhen Qiu; Hui-Yan Luo; Zhi-Qiang Wang; Yu-Hong Li; Feng-Hua Wang; Rui-Hua Xu
Journal: Sci Rep Date: 2015-12-01 Impact factor: 4.379

Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning?

Review 1. Emerging targeted agents in metastatic breast cancer.

2. VEGF₁₆₅b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop.

Review 3. Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.

4. A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.

5. Combining functional genomics strategies identifies modular heterogeneity of breast cancer intrinsic subtypes.

6. A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer.

Review 7. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.

8. Role of the nervous system in cancer metastasis.

Review 9. Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials.

10. Elevated expression of syntenin in breast cancer is correlated with lymph node metastasis and poor patient survival.

Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning?

Review 1. Emerging targeted agents in metastatic breast cancer.

2. VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop.

Review 3. Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.

4. A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.

5. Combining functional genomics strategies identifies modular heterogeneity of breast cancer intrinsic subtypes.

6. A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer.

Review 7. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.

8. Role of the nervous system in cancer metastasis.

Review 9. Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials.

10. Elevated expression of syntenin in breast cancer is correlated with lymph node metastasis and poor patient survival.

2. VEGF₁₆₅b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop.